December 07, 2015.
President Obama has signed into law a bill that extends exclusivity periods for new drugs and biologics containing a controlled substance by changing the date they are considered to have been approved from the current FDA sign-off to when the Drug Enforcement Agency schedules them for sale. The move is reported by FDA News as "a win for drugmakers".
The law also allows a controlled drug or biologic to be sold before the DEA assigns it to a controlled substance schedule. According to FDA News, "It effectively resets the date of approval by requiring the agency to issue an interim final rule to place a product in a Controlled Substances Act schedule within 90 days of when the drug was approved by the FDA or when HHS sends a scheduling recommendation to the DEA, whichever comes later. A product can be marketed with the interim schedule as it awaits a final decision."
Can Data and AI Deliver Whole-Person Health?
July 9th 2024Executives in the life sciences and medical device industries see promise in artificial intelligence (AI) and medical technologies, but must also navigate the changing healthcare ecosystem, varied stakeholder needs, and the impact of AI on market access and commercialization strategies.